@article {7513,
	title = {Elotuzumab therapy for relapsed or refractory multiple myeloma},
	journal = {New England Journal of Medicine},
	volume = {373},
	year = {2015},
	note = {Cited By :160Export Date: 21 February 2017},
	month = {2015},
	pages = {621 - 631},
	abstract = {Background: Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with lenalidomide and dexamethasone in a phase 1b-2 study in patients with relapsed or refractory multiple myeloma. Methods: In this phase 3 study, we randomly assigned patients to receive either elotuzumab plus lenalidomide and dexamethasone (elotuzumab group) or lenalidomide and dexamethasone alone (control group). Coprimary end points were progression-free survival and the overall response rate. Final results for the coprimary end points are reported on the basis of a planned interim analysis of progression-free survival. Results: Overall, 321 patients were assigned to the elotuzumab group and 325 to the control group. After a median follow-up of 24.5 months, the rate of progression-free survival at 1 year in the elotuzumab group was 68\%, as compared with 57\% in the control group; at 2 years, the rates were 41\% and 27\%, respectively. Median progression-free survival in the elotuzumab group was 19.4 months, versus 14.9 months in the control group (hazard ratio for progression or death in the elotuzumab group, 0.70; 95\% confidence interval, 0.57 to 0.85; P<0.001). The overall response rate in the elotuzumab group was 79\%, versus 66\% in the control group (P<0.001). Common grade 3 or 4 adverse events in the two groups were lymphocytopenia, neutropenia, fatigue, and pneumonia. Infusion reactions occurred in 33 patients (10\%) in the elotuzumab group and were grade 1 or 2 in 29 patients. Conclusions: Patients with relapsed or refractory multiple myeloma who received a combination of elotuzumab, lenalidomide, and dexamethasone had a significant relative reduction of 30\% in the risk of disease progression or death. Copyright {\textcopyright} 2015 Massachusetts Medical Society. All rights reserved.},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84933569079\&doi=10.1056\%2fNEJMoa1505654\&partnerID=40\&md5=ebfafb9d968ec8e4d796bb4ac87de97e},
	author = {Lonial, S. and Dimopoulos, M. and Palumbo, A. and White, D. and Grosicki, S. and Spicka, I. and Walter-Croneck, A. and Moreau, P. and Mateos, M.-V. and Magen, H. and Belch, A. and Reece, D. and Beksac, M. and Spencer, A. and Oakervee, H. and Orlowski, R.Z. and Taniwaki, M. and R{\"o}llig, C. and Einsele, H. and Wu, K.L. and Singhal, A. and San-Miguel, J. and Matsumoto, M. and Katz, J. and Bleickardt, E. and Poulart, V. and Anderson, K.C. and Richardson, P.}
}
